Clinical Trial Update: Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma [NA]

View source ↗

Summary

Clinical trial update for anti-GD2 3F8 monoclonal antibody with GM-CSF in high-risk neuroblastoma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 3F8 monoclonal antibody (anti-GD2 monoclonal antibody)
• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | NA | Status: COMPLETED | Results posted: 2020-02-28